VIATRIS INC

Viatris Inc. (VTRS, CUSIP 92556V106) entered Q1 2026 with $11.2B of institutional 13F value across 982 institutional accounts — a holder breadth appropriate for a global pharmaceutical company whose primary business operates at the intersection of (1) generic and biosimilar pharmaceuticals (post-patent-expiry drugs across cardiovascular, CNS, dermatology, and hospital injectables), (2) off-patent branded drugs and established-product portfolios, and (3) active-pharmaceutical-ingredient (API) and contract-development-and-manufacturing (CDMO) services. The stock was created through the 2020 merger of Pfizer's Upjohn division (off-patent drugs) and Mylan N.V. (one of the largest generic pharmaceutical manufacturers), making Viatris structurally positioned as the dominant consolidated player in the generic-drug tier with a revenue base weighted toward volume-driven, low-margin, high-certainty cash flows. The defining Q1 signal is ten new positions opening across an already-diversified holder base of 982 — consistent with either value-oriented or income-oriented institutional managers building positions at the pharmaceutical-value tier, where Viatris's high dividend yield and discounted free-cash-flow profile are the primary attractions. For smart-money trackers, VTRS is most informative as a generic-pharmaceutical-barometer — its institutional flows track whether managers are rotating into the mature-pharma-and-generics sleeve as an income-and-value alternative to growth-biotech or innovative-pharma exposures.